Orchestra Biomed Holdings, INC 8-K filings

Orchestra BioMed Holdings, Inc. announced new executive compensation plans, including a cash bonus program tied to clinical trial milestones and financial objectives, alongside revised RSU vesting and salary increases for its CEO and COO.

Orchestra BioMed expects to receive up to $21 million in proceeds from the acquisition of its strategic holding, Vivasure Medical, by Haemonetics Corporation.

Orchestra BioMed Holdings, Inc. announced significant strategic financing totaling nearly $150 million and provided updates on its pivotal AVIM Therapy and Virtue SAB clinical trials.

Orchestra BioMed Holdings, Inc. highlights its pivotal-stage therapies, strategic partnerships, and over $147 million in new capital commitments to fund operations into Q4 2027.

Orchestra BioMed has entered new strategic agreements with Terumo, securing $30 million in funding and initiating its pivotal U.S. Virtue SAB clinical trial for coronary in-stent restenosis.

Orchestra BioMed Holdings, Inc. successfully completed a public offering and private placement, raising approximately $56.2 million to advance its AVIM therapy and Virtue SAB programs.

Orchestra BioMed Holdings, Inc. announced a significant $70 million capital infusion from Ligand Pharmaceuticals and Medtronic, alongside an expanded strategic collaboration with Medtronic to integrate AVIM therapy into future leadless pacemakers.

Orchestra BioMed Holdings, Inc. announced the successful election of three Class II directors and the ratification of Ernst & Young LLP as its independent auditor at its 2025 Annual Meeting of Stockholders.

Orchestra BioMed announces FDA Breakthrough Device Designation for its AVIM therapy for hypertension and IDE approval for an updated Virtue Trial design for artery disease.

Orchestra BioMed's Q1 2025 investor presentation showcases progress in its hypertension and artery disease programs, emphasizing strategic partnerships and clinical trial advancements.

Orchestra BioMed Holdings announces updates to its executive compensation policies, including tax withholding on RSUs, a new cash bonus plan, and an equity award policy.

Orchestra BioMed appoints Christopher Cleary, former Medtronic SVP, to its Board of Directors and announces Eric Rose's transition to Emeritus Board Member and Strategic Advisor.

Orchestra BioMed Holdings, Inc. has entered into a new sales agreement with TD Securities for a potential $100 million at-the-market offering of its common stock, while terminating a previous agreement with Jefferies.

Orchestra BioMed has appointed John Mack, a seasoned medical device executive, to its Board of Directors, effective July 29, 2024.

Orchestra BioMed Holdings held its 2024 Annual Meeting of Stockholders, where shareholders voted on the election of directors and the ratification of the company's independent auditor.

Orchestra BioMed presented updates on its AVIM therapy for hypertension, including the ongoing BACKBEAT pivotal trial and positive data from previous studies, at its R&D Day.

Orchestra BioMed Holdings, Inc. has announced its first Annual Meeting of Stockholders will be held on June 20, 2024, with key dates set for shareholder proposals and director nominations.

Orchestra BioMed's Q1 2024 presentation outlines advancements in their pipeline, strategic partnerships, and financial outlook, including a cash runway into the second half of 2026.